MY CANCER GENOME

May 2013 Volume 1, Issue 1

In This Issue

New Disease Content

Chronic Myeloid Leukemia

Targeted Therapeutics List

Bladder Cancer

Updated Genes on MCG

BCR-ABL

TSC1

Articles of Interest

Gautschi O et al. A patient with lung adenocarcinoma and RET fusion treated with vandetanib. J Thorac Oncol 2013. May;8(5):e43-4.

Rudin CM et al. Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer. J Thorac Oncol

What's New on My Cancer Genome

Over the past year, My Cancer Genome has rapidly expanded to include 10 new diseases, 7 new genes and associated variants for a total of 18 diseases and 27 genes on My Cancer Genome.

The new diseases include acute lymphoblastic leukemia, anaplastic large cell lymphoma, basal cell carcinoma, chronic myeloid leukemia, gastric cancer, inflammatory myofibroblastic tumor, medulloblastoma, neuroblastoma, ovarian cancer, and rhabdomyosarcoma.

This new content provides our current total of 305 disease–gene–variant relationships (this can be thought of as the total number of variant pages in the disease content). We have also expanded our molecular medicine content to include our Targeted Therapeutics list.

For new features, we released our new My Cancer Genome logo in April 2012, added the “Give” option in December, and implemented the Google Search Option to allow for customized searching throughout the entire site in January 2013.

Our growth in 2012 would not have been possible without our contributors. We thank you for all of your hard work and support. Please continue to contribute and update this content this year, as we expand our content, audience and community.

My Cancer Genome Profiled in the New York Times

In an article on April 28th, 2013, entitled Variations on a Gene, and Tools to Find Them, Anne Eisenberg of the New York Times interviewed Dr. William Pao and profiled My Cancer Genome, along with several other companies providing tools for genetic testing and

2013. Epub Mar 21.

Yeh P et al. DNA-mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): A catalogue of clinically relevant cancer mutations to enable genome-directed cancer therapy. CCR 2013 Apr 1; 19(7): 1–8.

analysis of results. Read the article here. This and other recent mentions in the media, articles and publications can be found in our Mentions Section.

Contact Us

mycancergenome@vanderbilt.edu

www.mycancergenome.org

Contributor Highlight & Call for Contributors

A. Shaver, M.D., Ph.D.

New chronic myeloid leukemia content was written by:

Aaron Shaver , M.D., Ph.D.

Assistant Professor, Department of Pathology, Microbiology and Immunology, Vanderbilt University

Madan Jagasia , M.B.B.S., M.S.

Associate Professor of Medicine; Director, Outpatient Transplant Program; Section Chief, Hematology and Stem Cell Transplant, Vanderbilt University

M. Jagasia, M.B.B.S., M.S.

My Cancer Genome contributors currently provide content for a variety of oncologic malignancies and associated genes. However, the current content is not complete. In 2013, we continue to update the website regularly, covering new genes and diseases.

No one person or institution can keep up with the pace and volume of data that is emerging. As a collaborative network, we can move the field forward more quickly. If you or a colleague has expertise in a content area not covered, please contact mycancergenome@vanderbilt.edu to learn more about becoming a contributor.

Trial Design Highlight: Related Content on My Cancer Genome

Non-Small Cell Lung Cancer

RET Fusions in NSCLC

Cabozantinib in Drug List

Clinical Trial Search

RET-Associated Non-Small Cell Lung Cancer Clinical Trial

Trial Design Highlight:

Cabozantinib in Patients With KIF5B/RET Positive Advanced Non-Small Cell Lung Cancer (NCT01639508)

- Cabozantinib is a potent VEGFR2 inhibitor that also inhibits MET, RET, KIT, FLT-1/3/4, TIE2, and AXL
- This is the first clinical study of cabozantinib in KIF5B/RET or RET fusion positive NSCLC patients

- This phase II study will enroll 25 patients
- Patients must have metastatic or unresectable NSCLC
- Documented presence of KIF5B/RET or related variant RET fusions
- Study design: 28-day cycles of single agent cabozantinib given at 60 mg orally daily until disease progression or unacceptable drug-related toxicity